European Pharmaceutical Review

MAY 24, 2023

The US Food and Drug Administration (FDA) has approved the first-ever redosable gene therapy for the rare skin disease dystrophic epidermolysis bullosa (DEB). DEB affects the skin and mucosal tissues caused by one or more mutations in the COL7A1 gene, according to Krystal Biotech. The “landmark approval” declared Krish S.

99

99

Pharmaceutical Technology

MAY 30, 2023

Nidlegy is a new anti-cancer biopharmaceutical being developed to treat patients with melanoma and non-melanoma skin cancers. It is currently undergoing Phase III clinical studies. Sun Pharma has been granted exclusive commercialisation rights for Nidlegy in the three countries for the treatment of skin cancers.

52

52

European Pharmaceutical Review

OCTOBER 9, 2022

Research published in the journal Nature Chemistry , shows how researchers from Stanford University in the US uncovered a promising new method to synthetically manufacture the compound tigilanol tiglate, named EBC-46, which could offer targeted medicine for cancer and other diseases.

Compounding 134

Compounding Drug Development 134

Pharmacy Times

DECEMBER 5, 2023

Patients enrolled in the study had substantial absolute risks and elevated relative risks, suggesting that AKs may be a clinical marker of UV exposure and increased skin cancer risk.

49

49

Pharmaceutical Technology

DECEMBER 5, 2023

Pacmilimab is under clinical development by CytomX Therapeutics and currently in Phase II for Skin Cancer.

40

40

Pharmaceutical Technology

DECEMBER 5, 2023

Pacmilimab is under clinical development by CytomX Therapeutics and currently in Phase II for Skin Cancer.

40

40

RX Note

JULY 16, 2023

Resolution, with skin peeling, takes 4 to 7 days. There is ofen peeling of the sunburnt skin. Management involves the symptomatic treatment of skin inflammation and control of pain. ibuprofen) may be used for the treatment of skin pain and inflammation. Oral NSAIDs (e.g.

Mayo Clinic 52

Mayo Clinic 52

European Pharmaceutical Review

SEPTEMBER 26, 2022

At the 2022 European Society for Medical Oncology Congress (ESMO) conference, promising results from a Phase I trial, suggesting that a novel genetically modified (GM) herpes virus eradicated or reduced advanced cancers, were presented. After taking part in the trial, their cancers shrunk.

Immunity 94

Immunity Immunization 94

PharmaShots

MAY 30, 2023

skin cancer. Post-commercialization costs will be split equally b/w 2 companies in a ratio (50:50) Philogen intends to complete pivotal clinical studies for Nidlegy in the EU & seek marketing authorization from the regulatory authorities, will also be involved in the manufacture of commercial supplies.

40

40

European Pharmaceutical Review

DECEMBER 12, 2023

He discusses why NK cell therapy’s ability to generate ‘synthetic immunity’ in the body means this modality holds potential as an anti-cancer treatment. Innate Pharma is an international clinical-stage biotechnology oncology company based in France. Can you describe Innate Pharma’s clinical stage pipeline?

Immunity 110

Immunity Immunization Chemotherapy Pharmaceutical Companies 110

RX Note

JULY 15, 2023

Introduction Atopic dermatitis (eczema) is a chronic, pruritic, inflammatory skin disease that occurs most frequently in children but also affects many adults. Maintaining Skin Hydration Skin hydration is a key component of the overall management of patients with atopic dermatitis.

52

52

Express Pharma

JULY 27, 2023

We thank the patients, investigators, and clinical trial sites across the world for helping us advance our efforts in this area.” The companies also plan to expand the development program to additional tumor types, including non-small cell lung cancer.

Research Laboratories 92

Research Laboratories 92

pharmaphorum

DECEMBER 14, 2022

The mRNA technology that was deployed so effectively in vaccines against COVID-19 has now been found to offer similar promise against cancer, according to Merck & Co and Moderna. The vaccine primes the immune system to attack the tumour cells, while Keytruda blocks an immunological ‘brake’ that protects the cancer.

Vaccines 98

Vaccines Immunity Immunization 98

PharmaShots

MARCH 22, 2023

Lumisight received the FTD from the US FDA and Lumicell DVS received BTD Ref: Businesswire | Image: Lumicell Related News:- DermaSensor Presents Pooled analysis Results from the (DERM-ASSESS III) & (DERM-SUCCESS) Clinical Studies of Skin Cancer Detection Device

40

40

Board Vitals - Pharmacist

MARCH 5, 2024

Dermatologists are medical professionals who specialize in diagnosing and treating disorders related to the skin, hair, and nails. You’ll also gain practical experience through clinical rotations. These exams assess your knowledge and clinical skills in dermatology. The ABD BASIC Exam is given to first-year residents.

Medical Schools 52

Medical Schools 52

pharmaphorum

APRIL 20, 2022

Regeneron has agreed an all-cash deal to acquire CheckMate Pharmaceuticals, adding immune activator vidutolimod to its cancer immunotherapy pipeline and ending a barren spell for M&A in the biotech sector. Readouts from phase 2 studies in head and neck and non-melanoma skin cancer patients are due in the second half of 2022.

Immunity 52

Immunity Immunization 52

pharmaphorum

JANUARY 28, 2022

Merck & Co has passed another milestone in its drive to move PD-1 inhibitor Keytruda earlier in the treatment pathway for cancer, with the European Commission approving use of the drug as post-surgery (adjuvant) therapy for renal cell carcinoma (RCC). The post Merck gets EU nod for Keytruda in adjuvant kidney cancer appeared first on.

Research Laboratories 109

Research Laboratories 109

European Pharmaceutical Review

AUGUST 10, 2023

Talquetamab as a first-in-class therapy is a new option for patients with this difficult-to-treat blood cancer ,” stated Dr Ajai Chari, Director of Multiple Myeloma Program, Professor of Clinical Medicine at the University of California, US.

Pharmaceutical Companies 98

Pharmaceutical Companies Pharmaceutical Companies 98

PharmaShots

MARCH 24, 2023

PTC Therapeutics’ Upstaza (eladocagene exuparvovec) Receives NICE Recommendation for the Treatment of AADC Deficiency Date: Mar 24, 2023 | Tags: PTC Therapeutics, Upstaza, eladocagene exuparvovec, AADC Deficiency, Regulatory, NICE Onconova Therapeutics Entered into a Research Collaboration with Pangea Biomed to Identify Biomarkers for Cancer (..)

Diabetes 64

Diabetes Immunity Immunization Biosimilars 64

pharmaphorum

SEPTEMBER 22, 2021

Software that can help pathologists detect prostate cancer from slides of biopsies more effectively has been approved by the FDA. The approval is based on a clinical study where expert pathologists examined slide images of prostate biopsies – some with cancer and some without.

105

105

pharmaphorum

JANUARY 18, 2022

Cancer Research UK’s Centre for Drug Development, working with the Ludwig Institute for Cancer Research and Vaccitech, has begun a phase I/IIa clinical trial of a new lung cancer vaccine. Nigel Blackburn, director of cancer research UK’s Centre for Drug Development, said in a statement.

Immunity 62

Immunity Immunization Vaccines Drug Development 62

Express Pharma

APRIL 30, 2024

From cancer theragnostic agents to bioactive wound dressings for diabetic wounds, the facility will accelerate the development of diverse products for healthcare and environmental sustainability.” In his address, Prof. or a major accident, can send a lower middle class or poor family into abject penury.

Documentation 52

Documentation Diabetes Hospitals 52

Express Pharma

SEPTEMBER 18, 2023

They will also highlight: DAMAE Medical’s portable microscope for detecting skin cancer; Dynocardia’s blood pressure monitoring solution; FEops’ cardiac monitoring; LUCID Implants’ customised facial implants; and the VORTHEx radiotherapy simulation experience.

Documentation 98

Documentation Communication Vaccines 98

Pharmaceutical Technology

MARCH 17, 2023

The latest approval represents the sixth for the combination therapy, which is also indicated across several BRAF V600 solid tumours, including lung cancer, melanoma, and thyroid cancer. The regulatory approval is based on the data obtained from the Phase II/III TADPOLE trial.

Adverse Reactions 52

Adverse Reactions Chemotherapy 52

pharmaphorum

NOVEMBER 2, 2020

Although the company’s share price has been notoriously volatile, the NK-cell technology is still largely unproven in clinic. While Kiadis’ technology is mainly intended for cancer, the biotech announced plans in August to develop a NK-cell therapy for COVID-19, sending its shares soaring before they fell back due to profit-taking.

98

98

LifeProNow

MAY 8, 2023

The approval by the National Medical Products Administration (NMPA) in China was based on positive results from the SPRINT Stratum 1 trial sponsored by the National Institutes of Health’s National Cancer Institute (NCI) Cancer Therapy Evaluation Program (CTEP).

Adverse Reactions 100

Adverse Reactions Hospitals 100

pharmaphorum

AUGUST 2, 2022

The results of the IMscin001 study found that an injection of Tecentriq under the skin taking just a few minutes was non-inferior to a 30 to 60-minute infusion with the IV version in terms of pharmacokinetics – how the active ingredient behaves in the body after administration.

Chemotherapy 104

Chemotherapy Biosimilars 104

European Pharmaceutical Review

NOVEMBER 3, 2022

In total there are some 524 microbiome therapeutics – 48 percent in pre-clinical development and 42 percent in clinical development – with live biotherapeutics products dominating (177 therapeutics). For example, the design of clinical trials, the IP laws – how can you patent live microbial environments – and safety profiles.

Communication 85

Communication 85

pharmaphorum

SEPTEMBER 30, 2022

Simcere has taken SIM0278 to the brink of clinical testing, and says the drug can be delivered by subcutaneous injection to activate regulatory T cells (Tregs) that have been shown to dampen down inflammatory responses in preclinical disease models.

Immunity 52

Immunity Immunization 52

RX Note

NOVEMBER 3, 2023

Maternal health benefits may include reduced risk of some chronic diseases and cancer. Overview of Postpartum Care All infants should be placed skin-to-skin with the mother immediately after either vaginal or caesarean birth, unless medically contraindicated (e.g. An effective latch should also be clinically evaluated.

Hospitals 52

Hospitals Community Pharmacies 52

FADIC

OCTOBER 20, 2023

Instead, your body produces vitamin D when sunlight directly hits your skin, not through a window. Most importantly, vitamin E is an antioxidant that helps fight carcinogens and other cancer-causing agents. It makes collagen, a potent protein that helps wounds heal by providing the structure for your muscles, bones, and skin.

Immunity 89

Immunity Immunization Dosage Patient Counseling 89

PharmaShots

JUNE 2, 2023

Impact Therapeutics Entered into a License and Collaboration Agreement with Eikon Therapeutics to Develop and Commercialize IMP1734 Date: June 02, 2023 | Tags: Impact Therapeutics, Eikon Therapeutics, IMP1734, Pharma, China, Hong Kong, Macau, Taiwan BMS’ Mavacamten Receives the NICE Recommendation for the Treatment of Obstructive Hypertrophic (..)

Biosimilars 40

Biosimilars 40

PharmaShots

MARCH 24, 2023

PTC Therapeutics’ Upstaza (eladocagene exuparvovec) Receives NICE Recommendation for the Treatment of AADC Deficiency Date: Mar 24, 2023 | Tags: PTC Therapeutics, Upstaza, eladocagene exuparvovec, AADC Deficiency, Regulatory, NICE Onconova Therapeutics Entered into a Research Collaboration with Pangea Biomed to Identify Biomarkers for Cancer (..)

Diabetes 40

Diabetes Immunity Immunization Biosimilars 40

pharmaphorum

AUGUST 6, 2021

Sanofi and Regeneron’s latecomer checkpoint inhibitor Libtayo has largely been protected from heavyweight competition in its first niche markets, but now looks set to for a toe-to-toe contest with Merck & Co’s class leader Keytruda in the big non-small cell lung cancer (NSCLC) category.

Chemotherapy 65

Chemotherapy Labelling 65

Board Vitals - Pharmacist

JANUARY 18, 2023

Now, just as we reach for that cookie or carrot, imagine if our apps could audit the efficacy or quality of our real-time activities and health choices—then compare those choices or decisions with those of professional athletes or clinical dietitians? At many medical schools across and beyond the U.S.,

Medical Schools 52

Medical Schools HIPAA Communication 52

European Pharmaceutical Review

FEBRUARY 26, 2024

Clinical data showed approximately 60 percent reductions in plasma NfL concentrations in patients given Qalsody compared to placebo. Treating NSCLC Tizveni (tislelizumab) received a positive opinion from the CHMP for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) in adults.

Generic Medicine 91

Generic Medicine Vaccines Pharmaceutical Companies Pharmaceutical Companies 91

The Thyroid Pharmacist

JANUARY 27, 2023

In my survey of over 2000 people with Hashimoto’s , 57 percent of people who used a sauna reported that this made them feel significantly better; about 52 percent of the sauna users said they had more energy, about 41 percent reported improvements in skin health and pain levels, and additional improvements were seen in mood and even weight!

Diabetes 98

Diabetes Immunity Immunization Packaging 98